JP6964593B2 - ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン - Google Patents

ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン Download PDF

Info

Publication number
JP6964593B2
JP6964593B2 JP2018540013A JP2018540013A JP6964593B2 JP 6964593 B2 JP6964593 B2 JP 6964593B2 JP 2018540013 A JP2018540013 A JP 2018540013A JP 2018540013 A JP2018540013 A JP 2018540013A JP 6964593 B2 JP6964593 B2 JP 6964593B2
Authority
JP
Japan
Prior art keywords
treatment
administered
day
compound
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018540013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507134A5 (enExample
JP2019507134A (ja
Inventor
アラン エフ． リスト，
デイビッド エー． サルマン，
ジョン エス． コバック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019507134A publication Critical patent/JP2019507134A/ja
Publication of JP2019507134A5 publication Critical patent/JP2019507134A5/ja
Application granted granted Critical
Publication of JP6964593B2 publication Critical patent/JP6964593B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018540013A 2016-01-27 2017-01-27 ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン Expired - Fee Related JP6964593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287858P 2016-01-27 2016-01-27
US62/287,858 2016-01-27
PCT/US2017/015237 WO2017132445A1 (en) 2016-01-27 2017-01-27 Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor

Publications (3)

Publication Number Publication Date
JP2019507134A JP2019507134A (ja) 2019-03-14
JP2019507134A5 JP2019507134A5 (enExample) 2020-03-12
JP6964593B2 true JP6964593B2 (ja) 2021-11-10

Family

ID=59398691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540013A Expired - Fee Related JP6964593B2 (ja) 2016-01-27 2017-01-27 ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン

Country Status (6)

Country Link
US (2) US20190111053A1 (enExample)
EP (1) EP3407887B1 (enExample)
JP (1) JP6964593B2 (enExample)
CN (1) CN109475543A (enExample)
CA (1) CA3051828A1 (enExample)
WO (1) WO2017132445A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909160C (en) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
EP3736275B1 (en) 2015-05-15 2024-07-03 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs for use in treating cancer
US20190240290A1 (en) * 2016-08-04 2019-08-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Companion diagnostic for combination lenalidomide and erythropoietin treatment
JP7246309B2 (ja) 2016-12-08 2023-03-27 リクスト・バイオテクノロジー，インコーポレイテッド 免疫応答を調節するためのオキサビシクロヘプタン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267947A1 (en) 2006-09-07 2008-10-30 Cirrito Thomas P Cancer therapy with cantharidin and cantharidin analogs
CN101662939B (zh) * 2007-02-06 2015-11-25 利克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途
CA2909160C (en) * 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
US10071094B2 (en) * 2014-07-24 2018-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
EP3191096A4 (en) * 2014-09-12 2018-03-21 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor

Also Published As

Publication number Publication date
CN109475543A (zh) 2019-03-15
WO2017132445A8 (en) 2018-12-20
US20220184066A1 (en) 2022-06-16
US20220323433A2 (en) 2022-10-13
EP3407887A4 (en) 2019-09-25
JP2019507134A (ja) 2019-03-14
CA3051828A1 (en) 2017-08-03
EP3407887A1 (en) 2018-12-05
US20190111053A1 (en) 2019-04-18
EP3407887B1 (en) 2021-09-01
WO2017132445A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
US20220323433A2 (en) Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
US11337983B2 (en) Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
CN103501785B (zh) 用于治疗脑肿瘤的csf-1r抑制剂
KR102613106B1 (ko) Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙
JP2021517582A (ja) 細胞外ヒストンによって媒介される病理を処置及び予防するための化合物
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
Bi et al. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage
JP7285001B2 (ja) サフラナール製剤による肝臓癌治療の方法
EP4095137A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
CN113260361A (zh) 使用免疫调节治疗癌症的新型方法
JP2024519342A (ja) 自己免疫性、同種免疫性、炎症性、及びミトコンドリア性の状態を治療するための組成物、ならびにその使用
CN116492342B (zh) 氯喹或羟氯喹在制备治疗尼洛替尼肾脏毒副作用药物中的应用
US11918550B2 (en) Sensitization of cancer cells to differentiation therapy with mitochondrial uncoupler niclosamide ethanolamine
CN104334192A (zh) 使用pi3k抑制剂和mek抑制剂治疗癌症的方法
WO2025241125A1 (zh) 度洛西汀及化疗药物用于制备用于治疗或预防癌症的医药组成物的用途
WO2022175858A1 (en) Dicarboximide derivative for use in cancer treatment
WO2024137472A2 (en) Combination therapies
HK40085748A (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
JP2020132626A (ja) サフラナール製剤によるｃｄｃ２５ｂの抑制および阻害
JP2020176145A (ja) 血液癌の併用療法
HK40003387B (zh) 用於治疗胰腺癌的治疗性组合物
JP2019112389A (ja) 膵臓癌を処置するための治療用組成物
CN109195606A (zh) 用于治疗晚期非小细胞肺癌的方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211019

R150 Certificate of patent or registration of utility model

Ref document number: 6964593

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees